The Tumor Suppressor Protein TRAF3 Modulates GSK3 Activity and Susceptibility of B Lymphoma Cells to GSK3 Inhibition
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Mice
2.2. Cells and Treatment
2.3. Immunoprecipitation
2.4. Western Blotting
2.5. Statistical Analysis
3. Results
3.1. TRAF3 Association with GSK3β in BCL-Derived B Cells
3.2. TRAF3 Regulation of the Ratio of Inactive: Total GSK3β in Malignant B Cells
3.3. Impact of TRAF3 on Susceptibility of B Cells to GSK3-Mediated Inhibition of Survival
3.4. Involvement of Mcl1 in How TRAF3 Status Predicts 9-ING-41 Susceptibility of BCL Cells
3.5. Correction of Enhanced IL-6 Receptor Signaling in TRAF3-Deficient Malignant B Cells via GSK3 Inhibition
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Shaffer, A.L.; Young, R.M.; Staudt, L.M. Pathogenesis of Human B Cell Lymphomas. Annu. Rev. Immunol. 2012, 30, 565–610. [Google Scholar] [CrossRef]
- Shi, J.H.; Sun, S.C. Tumor Necrosis Factor Receptor-Associated Factor Regulation of Nuclear Factor κB and Mitogen-Activated Protein Kinase Pathways. Front. Immunol. 2018, 9, 1849. [Google Scholar] [CrossRef]
- Bishop, G.A.; Stunz, L.L.; Hostager, B.S. TRAF3 as a Multifaceted Regulator of B Lymphocyte Survival and Activation. Front. Immunol. 2018, 9, 2161. [Google Scholar] [CrossRef] [Green Version]
- Xie, P.; Stunz, L.L.; Larison, K.D.; Yang, B.; Bishop, G.A. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 2007, 27, 253–267. [Google Scholar] [CrossRef] [Green Version]
- Lin, W.W.; Yi, Z.; Stunz, L.L.; Maine, C.J.; Sherman, L.A.; Bishop, G.A. The adaptor protein TRAF3 inhibits interleukin-6 receptor signaling in B cells to limit plasma cell development. Sci. Signal. 2015, 8, ra88. [Google Scholar] [CrossRef] [Green Version]
- Mambetsariev, N.; Lin, W.W.; Wallis, A.M.; Stunz, L.L.; Bishop, G.A. TRAF3 deficiency promotes metabolic reprogramming in B cells. Sci. Rep. 2016, 6, 35349. [Google Scholar] [CrossRef] [Green Version]
- Xie, P.; Poovassery, J.; Stunz, L.L.; Smith, S.M.; Schultz, M.L.; Carlin, L.E.; Bishop, G.A. Enhanced Toll-like receptor (TLR) responses of TNFR-associated factor 3 (TRAF3)-deficient B lymphocytes. J. Leukoc. Biol. 2011, 90, 1149–1157. [Google Scholar] [CrossRef] [Green Version]
- Chen, Z.; Krinsky, A.; Woolaver, R.A.; Wang, X.; Chen, S.M.Y.; Popolizio, V.; Xie, P.; Wang, J.H. TRAF3 Acts as a Checkpoint of B Cell Receptor Signaling to Control Antibody Class Switch Recombination and Anergy. J. Immunol. 2020, 205, 830–841. [Google Scholar] [CrossRef]
- Moore, C.R.; Liu, Y.; Shao, C.; Covey, L.R.; Morse, H.C., 3rd; Xie, P. Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice. Leukemia 2012, 26, 1122–1127. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bushell, K.R.; Kim, Y.; Chan, F.C.; Ben-Neriah, S.; Jenks, A.; Alcaide, M.; Fornika, D.; Grande, B.M.; Arthur, S.; Gascoyne, R.D.; et al. Genetic inactivation of TRAF3 in canine and human B-cell lymphoma. Blood 2015, 125, 999–1005. [Google Scholar] [CrossRef] [PubMed]
- Braggio, E.; Keats, J.J.; Leleu, X.; Van Wier, S.; Jimenez-Zepeda, V.H.; Valdez, R.; Schop, R.F.J.; Price-Troska, T.; Henderson, K.; Sacco, A.; et al. Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström’s Macroglobulinemia. Cancer Res. 2009, 69, 3579. [Google Scholar] [CrossRef] [Green Version]
- Keats, J.J.; Fonseca, R.; Chesi, M.; Schop, R.; Baker, A.; Chng, W.-J.; Van Wier, S.; Tiedemann, R.; Shi, C.-X.; Sebag, M.; et al. Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma. Cancer Cell 2007, 12, 131–144. [Google Scholar] [CrossRef] [Green Version]
- Annunziata, C.M.; Davis, R.E.; Demchenko, Y.; Bellamy, W.; Gabrea, A.; Zhan, F.; Lenz, G.; Hanamura, I.; Wright, G.; Xiao, W.; et al. Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma. Cancer Cell 2007, 12, 115–130. [Google Scholar] [CrossRef] [Green Version]
- Xie, P.; Hostager, B.S.; Bishop, G.A. Requirement for TRAF3 in signaling by LMP1 but not CD40 in B lymphocytes. J. Exp. Med. 2004, 199, 661–671. [Google Scholar] [CrossRef] [Green Version]
- Bangalore-Prakash, P.; Stunz, L.L.; Mambetsariev, N.; Whillock, A.L.; Hostager, B.S.; Bishop, G.A. The oncogenic membrane protein LMP1 sequesters TRAF3 in B-cell lymphoma cells to produce functional TRAF3 deficiency. Blood Adv. 2017, 1, 2712–2723. [Google Scholar] [CrossRef] [Green Version]
- Manning, B.D.; Toker, A. AKT/PKB Signaling: Navigating the Network. Cell 2017, 169, 381–405. [Google Scholar] [CrossRef] [Green Version]
- Hoffmeister, L.; Diekmann, M.; Brand, K.; Huber, R. GSK3: A Kinase Balancing Promotion and Resolution of Inflammation. Cells 2020, 9, 820. [Google Scholar] [CrossRef] [Green Version]
- Augello, G.; Emma, M.R.; Cusimano, A.; Azzolina, A.; Montalto, G.; McCubrey, J.A.; Cervello, M. The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment. Cells 2020, 9, 1427. [Google Scholar] [CrossRef]
- Wu, X.; Stenson, M.; Abeykoon, J.; Nowakowski, K.; Zhang, L.; Lawson, J.; Wellik, L.; Li, Y.; Krull, J.; Wenzl, K.; et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood 2019, 134, 363–373. [Google Scholar] [CrossRef]
- Harrington, C.T.; Sotillo, E.; Robert, A.; Hayer, K.E.; Bogusz, A.M.; Psathas, J.; Yu, D.; Taylor, D.; Dang, C.V.; Klein, P.; et al. Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Leukemia 2019, 33, 2429–2441. [Google Scholar] [CrossRef]
- Jellusova, J.; Cato, M.H.; Apgar, J.R.; Ramezani-Rad, P.; Leung, C.R.; Chen, C.; Richardson, A.D.; Conner, E.M.; Benschop, R.J.; Woodgett, J.R.; et al. Gsk3 is a metabolic checkpoint regulator in B cells. Nat. Immunol. 2017, 18, 303–312. [Google Scholar] [CrossRef] [Green Version]
- Lee, J.; Park, H.; Lim, J.; Jin, H.-S.; Park, Y.; Jung, Y.-J.; Ko, H.-J.; Yoon, S.-I.; Lee, G.-S.; Kim, P.-H.; et al. GSK3 Restrains Germinal Center B Cells to Form Plasma Cells. J. Immunol. 2021, 206, 481. [Google Scholar] [CrossRef]
- Thornton, T.M.; Delgado, P.; Chen, L.; Salas, B.; Krementsov, D.; Fernandez, M.; Vernia, S.; Davis, R.J.; Heimann, R.; Teuscher, C.; et al. Inactivation of nuclear GSK3β by Ser389 phosphorylation promotes lymphocyte fitness during DNA double-strand break response. Nat. Commun. 2016, 7, 10553. [Google Scholar] [CrossRef]
- Mambetsariev, N.; Lin, W.W.; Stunz, L.L.; Hanson, B.M.; Hildebrand, J.M.; Bishop, G.A. Nuclear TRAF3 is a negative regulator of CREB in B cells. Proc. Natl. Acad. Sci. USA 2016, 113, 1032–1037. [Google Scholar] [CrossRef] [Green Version]
- Whillock, A.L.; Mambetsariev, N.; Lin, W.W.; Stunz, L.L.; Bishop, G.A. TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells. Sci. Rep. 2019, 9, 12884. [Google Scholar] [CrossRef] [Green Version]
- Kim, K.J.; Kanellopoulos-Langevin, C.; Merwin, R.M.; Sachs, D.H.; Asofsky, R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J. Immunol. 1979, 122, 549–554. [Google Scholar]
- Menezes, J.; Leibold, W.; Klein, G.; Clements, G. Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt’s lymphoma. Biomedicine 1975, 22, 276–284. [Google Scholar]
- Tompkins, V.S.; Han, S.S.; Olivier, A.; Syrbu, S.; Bair, T.; Button, A.; Jacobus, L.; Wang, Z.; Lifton, S.; Raychaudhuri, P.; et al. Identification of candidate B-lymphoma genes by cross-species gene expression profiling. PLoS ONE 2013, 8, e76889. [Google Scholar] [CrossRef] [Green Version]
- Dyer, M.J.; Fischer, P.; Nacheva, E.; Labastide, W.; Karpas, A. A new human B-cell non-Hodgkin’s lymphoma cell line (Karpas 422) exhibiting both t (14;18) and t(4;11) chromosomal translocations. Blood 1990, 75, 709–714. [Google Scholar] [CrossRef] [Green Version]
- Tweeddale, M.E.; Lim, B.; Jamal, N.; Robinson, J.; Zalcberg, J.; Lockwood, G.; Minden, M.D.; Messner, H.A. The presence of clonogenic cells in high-grade malignant lymphoma: A prognostic factor. Blood 1987, 69, 1307–1314. [Google Scholar] [CrossRef] [Green Version]
- Klein, E.; Klein, G.; Nadkarni, J.S.; Nadkarni, J.J.; Wigzell, H.; Clifford, P. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 1968, 28, 1300–1310. [Google Scholar]
- Klein, G.; Lindahl, T.; Jondal, M.; Leibold, W.; Menézes, J.; Nilsson, K.; Sundström, C. Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proc. Natl. Acad. Sci. USA 1974, 71, 3283–3286. [Google Scholar] [CrossRef] [Green Version]
- Saiki, O.; Ralph, P. Clonal differences in response to T cell replacing factor (TRF) for IgM secretion and TRF receptors in a human B lymphoblast cell line. Eur. J. Immunol. 1983, 13, 31–34. [Google Scholar] [CrossRef]
- Krangel, M.S.; Orr, H.T.; Strominger, J.L. Assembly and maturation of HLA-A and HLA-B antigens in vivo. Cell 1979, 18, 979–991. [Google Scholar] [CrossRef]
- Wallis, A.M.; Wallace, E.C.; Hostager, B.S.; Yi, Z.; Houtman, J.C.D.; Bishop, G.A. TRAF3 enhances TCR signaling by regulating the inhibitors Csk and PTPN22. Sci. Rep. 2017, 7, 2081. [Google Scholar] [CrossRef] [Green Version]
- Ko, R.; Park, J.H.; Ha, H.; Choi, Y.; Lee, S.Y. Glycogen synthase kinase 3β ubiquitination by TRAF6 regulates TLR3-mediated pro-inflammatory cytokine production. Nat. Commun. 2015, 6, 6765. [Google Scholar] [CrossRef] [Green Version]
- Edwards, S.K.; Han, Y.; Liu, Y.; Kreider, B.Z.; Liu, Y.; Grewal, S.; Desai, A.; Baron, J.; Moore, C.R.; Luo, C.; et al. Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells. Leuk. Res. 2016, 41, 85–95. [Google Scholar] [CrossRef] [Green Version]
- Zhu, S.; Jin, J.; Gokhale, S.; Lu, A.M.; Shan, H.; Feng, J.; Xie, P. Genetic Alterations of TRAF Proteins in Human Cancers. Front. Immunol. 2018, 9, 2111. [Google Scholar] [CrossRef] [Green Version]
- Karmali, R.; Chukkapalli, V.; Gordon, L.I.; Borgia, J.A.; Ugolkov, A.; Mazar, A.P.; Giles, F.J. GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents. Oncotarget 2017, 8, 114924–114934. [Google Scholar] [CrossRef] [Green Version]
- Whillock, A.L.; Ybarra, T.K.; Bishop, G.A. TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells. J. Biol. Chem. 2021, 296, 100465. [Google Scholar] [CrossRef]
- Senichkin, V.V.; Streletskaia, A.Y.; Gorbunova, A.S.; Zhivotovsky, B.; Kopeina, G.S. Saga of Mcl-1: Regulation from transcription to degradation. Cell Death Differ. 2020, 27, 405–419. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.C.; Shi, Y.J.; Wang, L.J.; Chiou, J.T.; Huang, C.H.; Chang, L.S. GSK3β suppression inhibits MCL1 protein synthesis in human acute myeloid leukemia cells. J. Cell. Physiol. 2021, 236, 570–586. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hornick, E.L.; Stunz, L.L.; Sabree, S.; Wu, X.; Witzig, T.E.; Bishop, G.A. The Tumor Suppressor Protein TRAF3 Modulates GSK3 Activity and Susceptibility of B Lymphoma Cells to GSK3 Inhibition. Cancers 2022, 14, 5029. https://doi.org/10.3390/cancers14205029
Hornick EL, Stunz LL, Sabree S, Wu X, Witzig TE, Bishop GA. The Tumor Suppressor Protein TRAF3 Modulates GSK3 Activity and Susceptibility of B Lymphoma Cells to GSK3 Inhibition. Cancers. 2022; 14(20):5029. https://doi.org/10.3390/cancers14205029
Chicago/Turabian StyleHornick, Emma L., Laura L. Stunz, Shakoora Sabree, Xiaosheng Wu, Thomas E. Witzig, and Gail A. Bishop. 2022. "The Tumor Suppressor Protein TRAF3 Modulates GSK3 Activity and Susceptibility of B Lymphoma Cells to GSK3 Inhibition" Cancers 14, no. 20: 5029. https://doi.org/10.3390/cancers14205029